What is the average price target for NUTEX HEALTH INC (NUTX) stock?
9 analysts have analysed NUTX and the average price target is 255 USD. This implies a price increase of 168.48% is expected in the next year compared to the current price of 94.98.
NUTEX HEALTH INC (NUTX) Forecast, Price Target & Analyst Ratings
NASDAQ:NUTX • US67079U3068
Current stock price
94.98 USD
+5.99 (+6.73%)
At close:
94.98 USD
0 (0%)
After Hours:
Analyst forecast overview
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for NUTEX HEALTH INC (NUTX).
Forecast Snapshot
Next Earnings Forecast
Earnings Estimate- Release Date
- May 11, 2026
- Period
- Q1 / 2026
- EPS Estimate
- $5.13
- Revenue Estimate
- 236.94M
Price Target Details & History
Consensus Price Target and Range
Mean target
$255.00
Upside
+ 168.48%
From current price of $94.98 to mean target of $255.00, Based on 9 analyst forecasts
Low
$222.20
Median
$234.60
High
$315.00
Price Target Revisions
1 Month
0.00%
3 Months
0.00%
Price Target Summary
9 Wall Street analysts provided a forecast for the next 12 months for NUTX. The average price target is 255 USD. This implies a price increase of 168.48% is expected in the next year compared to the current price of 94.98.
Analyst Ratings & History
Current Analyst Ratings
Analyst Ratings History
Analyst Ratings Consensus
ChartMill Buy Consensus
82.22%
NUTX was analyzed by 9 analysts. The buy percentage consensus is at 82. So analysts seem to be very confident about NUTX.
In the previous month the buy percentage consensus was at a similar level.
NUTX was analyzed by 9 analysts. More opinions would make the average more meaningful.
Recent Upgrades & Downgrades
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2025-08-26 | Maxim Group | Maintains | Buy -> Buy |
| 2025-05-20 | Maxim Group | Maintains | Buy -> Buy |
| 2025-05-15 | Benchmark | Maintains | Buy -> Buy |
| 2025-04-08 | Maxim Group | Maintains | Buy -> Buy |
| 2025-02-13 | Maxim Group | Maintains | Buy -> Buy |
| 2024-11-12 | Benchmark | Maintains | Buy -> Buy |
| 2024-11-12 | Maxim Group | Maintains | Buy -> Buy |
| 2024-09-18 | Maxim Group | Initiate | Buy |
| 2024-08-21 | Benchmark | Maintains | Buy -> Buy |
| 2024-01-25 | Benchmark | Maintains | Buy -> Buy |
| 2023-11-14 | Benchmark | Maintains | Buy -> Buy |
| 2023-08-29 | Benchmark | Reiterate | Buy -> Buy |
| 2023-05-17 | Benchmark | Maintains | Buy -> Buy |
| 2023-03-09 | Benchmark | Reiterate | Buy |
| 2022-12-23 | Benchmark | Initiate | Buy |
Next Earnings Forecast Details
Next Earnings Details
- Release Date
- May 11, 2026
- Period
- Q1 / 2026
- EPS Estimate
- $5.13
- Revenue Estimate
- 236.94M
- Revenue Q2Q
- 11.88%
- EPS Q2Q
- 100.55%
- Number of Analysts
- 5
Next Earnings Revisions
Revenue (1 Month)
-6.90%
Revenue (3 Months)
-6.90%
EPS (1 Month)
-1.79%
EPS (3 Months)
-1.79%
Next Earnings Summary
NUTX is expected to report earnings on 5/11/2026. The consensus EPS estimate for the next earnings is 5.13 USD and the consensus revenue estimate is 236.94M USD.
The next earnings revenue estimate has been revised downward by 6.9% in the past 3 months. Downward revisions are a negative sign and indicate that analysts are more pessimistic about the next earnings compared to 3 months ago.
Full Analyst Estimates 2026 - 2027
Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates
| 2023 | 2024 | 2025 | 2026 | 2027 | ||
|---|---|---|---|---|---|---|
| Revenue YoY % growth | 247.646M 12.93% | 479.949M 93.80% | 875.257M 82.36% | 947.76M 8.28% | 966.36M 1.96% | |
| EBITDA YoY % growth | 16.3M 90.58% | 156.678M 861.21% | 296.155M 89.02% | 341.71M 15.38% | 443.43M 29.77% | |
| EBIT YoY % growth | -1.292M 71.78% | 137.706M 10,758.36% | 275.625M 100.15% | 360.71M 30.87% | 363.86M 0.87% | |
| Operating Margin | -0.52% | 28.69% | 31.49% | 38.06% | 37.65% | |
| EPS YoY % growth | -4.50 95.61% | 8.73 294.00% | 8.98 2.86% | 21.42 138.53% | 26.46 23.52% |
All data in USD
Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates
| Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | |
|---|---|---|---|---|
| EPS Q2Q % growth | 5.13 100.55% | 5.27 278.59% | 5.49 -29.28% | 5.09 216.45% |
| Revenue Q2Q % growth | 236.94M 11.88% | 250.76M 2.78% | 255.79M -4.49% | 263.86M 73.96% |
| EBITDA Q2Q % growth | 74.054M -4.20% | 80.59M 83.08% | 84.459M -42.04% | 86.241M 67.63% |
| EBIT Q2Q % growth | 89.119M 23.42% | 86.196M 155.93% | 91.617M -29.72% | 101.47M 228.19% |
All data in USD
Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data
Long Term Forward Growth Forecast Summary
Long Term EPS Growth (CAGR)
EPS Next 3 Year
N/A
EPS Next 5 Year
N/A
Long Term Revenue Growth (CAGR)
Revenue Next 3 Year
N/A
Revenue Next 5 Year
N/A
Long Term EBIT Growth (CAGR)
EBIT Next 3 Year
N/A
EBIT Next 5 Year
N/A
NUTEX HEALTH INC / NUTX Forecast FAQ
Can you provide the upcoming earnings date for NUTEX HEALTH INC?
NUTEX HEALTH INC (NUTX) will report earnings on 2026-05-11.
What are the consensus estimates for NUTX stock next earnings?
The consensus EPS estimate for the next earnings of NUTEX HEALTH INC (NUTX) is 5.13 USD and the consensus revenue estimate is 236.94M USD.
How do analysts rate NUTEX HEALTH INC (NUTX)?
The consensus rating for NUTEX HEALTH INC (NUTX) is 82.2222 / 100 . This indicates that analysts generally have a positive outlook on the stock.